Author(s)

ZhiGang Zhai¹, Yuan Fang², ZhenYu Xue³, Jian Guo⁴, Xiang Tang^5*

Affiliation(s)

¹Department of Thoracic Oncology, Affiliated Hospital of Jiangsu University, Zhenjiang 221001, Jiangsu, China.

²Department of Abdominal Oncology, Affiliated Hospital of Jiangsu University, Zhenjiang 221001, Jiangsu, China.

³Department of Head, Neck and Comprehensive Oncology, Affiliated Hospital of Jiangsu University, Zhenjiang 221001, Jiangsu, China.

⁴Department of Pathology, Affiliated Hospital of Jiangsu University, Zhenjiang 221001, Jiangsu, China.

Corresponding Author

Xiang Tang

ABSTRACT

Objective: To investigate the expression characteristics, clinical significance, molecular mechanisms, and drug sensitivity of Achaete-scute family BHLH transcription factor 2 (ASCL2) in esophageal cancer, and to clarify its value as a prognostic marker and potential therapeutic target for esophageal cancer. Methods: RNA sequencing data and clinical information of esophageal cancer were downloaded from The Cancer Genome Atlas (TCGA) database. After standardization, 163 samples were included. Bioinformatics methods were used to analyze the expression difference of ASCL2 and its correlation with clinicopathological features and prognosis. Maftools package was employed for gene mutation characteristic analysis, immunedeconv package for immune scoring and immune checkpoint-related gene analysis, Limma package and ClusterProfiler package for differential gene screening and GO/KEGG enrichment analysis, and Genomics of Drug Sensitivity in Cancer (GDSC) database for drug sensitivity prediction. Meanwhile, 20 pairs of esophageal cancer tissue samples were collected, and the expression level of ASCL2 was verified by quantitative real-time PCR (qRT-PCR). Results: Both bioinformatics analysis and clinical sample verification showed that the expression of ASCL2 in esophageal cancer tissues was significantly higher than that in adjacent normal tissues, and its expression was partially correlated with tumor differentiation grade and clinical stage. Survival analysis revealed that the median overall survival (OS) of patients in the ASCL2 high-expression subgroup was significantly shorter than that in the low-expression subgroup (1.9 years vs 3.2 years), and the area under the curve (AUC) of ASCL2 for predicting 5-year survival rate was 0.732, indicating that ASCL2 could serve as an independent prognostic factor for the overall survival of esophageal cancer patients. Differential gene and enrichment analysis showed that ASCL2-related differential genes were mainly enriched in lipid metabolism reprogramming, DNA damage repair, cell cycle regulation, as well as Wnt and TGF-beta signaling pathways. Drug sensitivity prediction indicated that the ASCL2 high-expression subgroup had significantly reduced sensitivity to paclitaxel and cisplatin. Conclusion: ASCL2 is highly expressed in esophageal cancer tissues and is closely associated with lymph node metastasis and poor prognosis of patients, which can be used as a potential biomarker for prognostic evaluation of esophageal cancer. ASCL2 may promote the malignant progression of esophageal cancer by interacting with TP53, constructing an inhibitory tumor immune microenvironment, regulating tumor-related signaling pathways, and reducing chemotherapeutic drug sensitivity, thus providing a new target for the personalized treatment of esophageal cancer.

KEYWORDS

ASCL2; Esophageal Cancer (ESCA); Prognosis; Bioinformatics; Drug sensitivity

CITE THIS PAPER

ZhiGang Zhai, Yuan Fang, ZhenYu Xue, Jian Guo, Xiang Tang. Bioinformatics-based prediction of the impact of ASCL2 on the prognosis of esophageal cancer. Journal of Computer Science and Electrical Engineering. 2026, 8(1): 1-10. DOI: https://doi.org/10.61784/jcsee3111.

REFERENCES

[1] Ling Q, Mengfei S, Weixin L, et al. Global esophageal cancer epidemiology in 2022 and predictions for 2050: a comprehensive analysis and projections based on GLOBOCAN data. Chinese Medical Journal, 2024, 137(24).

[2] Syed Adnan R, Yutong H. Cancer burden and attributable risk factors of cancers in China: epidemiological insights and comparisons with India. Cancer Control, 2024, 31(0).

[3] Yusheng W, Wei Y, Qianyun W, et al. Mechanisms of esophageal cancer metastasis and treatment progress. Frontiers in Immunology, 2023, 14(0).

[4] Yuanzhuo G, Zhengkui Z, Peter T D. Harnessing epithelial-mesenchymal plasticity to boost cancer immunotherapy. Cellular & Molecular Immunology, 2023, 20(4).

[5] Peter V, Heinz S, Arnulf M. The Warburg effect: essential part of metabolic reprogramming and central contributor to cancer progression. International Journal of Radiation Biology, 2019, 95(7).

[6] Jing Y, Di C, Zi Y, et al. Molecular mechanisms and therapeutic significance of tryptophan metabolism and signaling in cancer. Molecular Cancer, 2024, 23(1).

[7] Mojtaba K A A, Muhammad Ayaz A, Mahsa E, et al. Basic understanding and therapeutic approaches to target toll-like receptors in cancerous microenvironment and metastasis. Medicinal Research Reviews, 2017, 38(5).

[8] Allison N C, Gizem Karsli U, Petra C, et al. Locally acting transcription factors regulate p53-dependent cis-regulatory element activity. Nucleic Acids Research, 2020, 48(8).

[9] M A, M H, A K H, et al. The human Achaete-Scute homologue 2 (ASCL2, HASH2) maps to chromosome 11p15.5, close to IGF2 and is expressed in extravillus trophoblasts. Human Molecular Genetics, 1997, 6(6).

[10] J E J, S J B, D J A. Two rat homologues of Drosophila achaete-scute specifically expressed in neuronal precursors. Nature, 1990, 346(6287).

[11] Dan Z, Qi-Qi N, Qiao-Yan L, et al. ASCL2 induces an immune excluded microenvironment by activating cancer-associated fibroblasts in microsatellite stable colorectal cancer. Oncogene, 2023, 42(38).

[12] Kaela M V, Khursheed I, Masanaga M, et al. ASCL2 reciprocally controls key trophoblast lineage decisions during hemochorial placenta development. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118(10).

[13] Maude H, Zoéline M, Molly S, et al. ASCL2 is a key regulator of the proliferation-differentiation equilibrium in the esophageal epithelium. Biology Open, 2024, 13(1).

[14] Li Z L, Jung-Hyun K, Iliana H, et al. HMGA1 acts as an epigenetic gatekeeper of ASCL2 and Wnt signaling during colon tumorigenesis. Journal of Clinical Investigation, 2025, 135(3).

[15] Yulong Y, Qingjie M, Xianghua L, et al. ASCL2 contributes to clinical assessments of breast cancer and mediates tumor progression via the interaction with CLDN3. Scientific Reports, 2025, 16(1).

[16] Zhijie G, Weiwei W, Yinghao H, et al. Integrated multi-omics analysis identifies SRI as a critical target promoting gastric cancer progression and associated with poor prognosis. Cancers, 2025, 17(21).

[17] Lingshan Z, Yuan Y, Qian Q, et al. AKT1-mediated NOTCH1 phosphorylation promotes gastric cancer progression via targeted regulation of IRS-1 transcription. Journal of Cancer Research and Clinical Oncology, 2024, 151(1).

[18] Akueni L D, Silvia C, Liana L, et al. Aberrant TP53 detected by combining immunohistochemistry and DNA-FISH improves Barrett's esophagus progression prediction: a prospective follow-up study. Genes, Chromosomes & Cancer, 2014, 54(2).

[19] Chan Z, Lei L, Yanxiu L, et al. Engineered hUCMSC-derived extracellular vesicles deliver circ-0000258 to restore p53-mediated tumor suppression in papillary thyroid carcinoma. BMC Cancer, 2025, 25(1).

[20] Jiaao S, Jiahua L, Feng C, et al. Exploring the significance of fatty acid metabolism reprogramming in the pathogenesis of cancer and anticancer therapy. Annals of Medicine, 2025, 57(1).

[21] Sijia R, Xikai Z, Xiao Z, et al. First-line PD-1/PD-L1 inhibitors plus chemotherapy versus chemotherapy alone for advanced esophageal and gastroesophageal junction adenocarcinoma: a systematic review and meta-analysis of randomized controlled trials. Journal of Gastrointestinal Oncology, 2026, 16(6).